CLIMB BIO, INC. Operating Lease, Expense
CLIMB BIO, INC. (CLYM) reported Operating Lease, Expense of $57.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2026-08-06
- CLIMB BIO, INC. operating lease, expense for the quarter ending 2026-06-30 was -$1.00K, a 102.04% decline year-over-year.
- CLIMB BIO, INC. operating lease, expense for the quarter ending 2026-03-31 was $58.00K, a 48.72% increase year-over-year.
- CLIMB BIO, INC. operating lease, expense for the quarter ending 2025-12-31 was $57.00K, a 72.73% increase year-over-year.
- CLIMB BIO, INC. operating lease, expense for the quarter ending 2025-09-30 was $56.00K, a 522.22% increase year-over-year.
- CLIMB BIO, INC. operating lease, expense for fiscal 2025 was $201.00K, a 8.64% decline from fiscal 2024.
- CLIMB BIO, INC. operating lease, expense for fiscal 2024 was $220.00K, a 45.68% decline from fiscal 2023.
- CLIMB BIO, INC. operating lease, expense for fiscal 2023 was $405.00K, a 8.58% decline from fiscal 2022.
- CLIMB BIO, INC. operating lease, expense for fiscal 2022 was $443.00K.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $57.00K 10-Q · filed 2026-08-06 | $114.00K derived: sum of 3 quarters · filed 2026-08-06 | $170.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $58.00K 10-Q · filed 2026-05-07 | $115.00K derived: sum of 2 quarters · filed 2026-05-07 | $171.00K derived: sum of 3 quarters · filed 2026-05-07 | $220.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $57.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $113.00K derived: sum of 2 quarters · filed 2026-03-05 | $162.00K derived: sum of 3 quarters · filed 2026-08-06 | $201.00K 10-K · filed 2026-03-05 |
| 2025-09-30 | $56.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $105.00K derived: sum of 2 quarters · filed 2026-08-06 | $144.00K 10-Q · filed 2025-11-06 | $177.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $49.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $88.00K 10-Q · filed 2026-08-06 | $121.00K derived: sum of 3 quarters · filed 2026-08-06 | $130.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $39.00K 10-Q · filed 2026-05-07 | $72.00K derived: sum of 2 quarters · filed 2026-05-07 | $81.00K derived: sum of 3 quarters · filed 2026-05-07 | $171.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $33.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $42.00K derived: sum of 2 quarters · filed 2026-03-05 | $132.00K derived: sum of 3 quarters · filed 2026-03-05 | $220.00K 10-K · filed 2026-03-05 |
| 2024-09-30 | $9.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $99.00K derived: sum of 2 quarters · filed 2025-11-06 | $187.00K 10-Q · filed 2025-11-06 | $274.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $90.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $178.00K 10-Q · filed 2025-08-12 | $265.00K derived: sum of 3 quarters · filed 2025-08-12 | $351.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $88.00K 10-Q · filed 2025-05-14 | $175.00K derived: sum of 2 quarters · filed 2025-05-14 | $261.00K derived: sum of 3 quarters · filed 2025-05-14 | $371.00K derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $87.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | $173.00K derived: sum of 2 quarters · filed 2025-03-25 | $283.00K derived: sum of 3 quarters · filed 2025-03-25 | $405.00K 10-K · filed 2025-03-25 |
| 2023-09-30 | $86.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $196.00K derived: sum of 2 quarters · filed 2024-11-12 | $318.00K 10-Q · filed 2024-11-12 | $432.00K derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $110.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $232.00K 10-Q · filed 2024-08-14 | $346.00K derived: sum of 3 quarters · filed 2024-08-14 | $458.00K derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $122.00K 10-Q · filed 2024-05-15 | $236.00K derived: sum of 2 quarters · filed 2024-05-15 | $348.00K derived: sum of 3 quarters · filed 2024-05-15 | $457.00K derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $114.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $226.00K derived: sum of 2 quarters · filed 2024-03-28 | $335.00K derived: sum of 3 quarters · filed 2024-03-28 | $443.00K 10-K · filed 2024-03-28 |
| 2022-09-30 | $112.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $221.00K derived: sum of 2 quarters · filed 2023-11-14 | $329.00K 10-Q · filed 2023-11-14 | $329.00K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $109.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $217.00K 10-Q · filed 2023-08-10 | $217.00K derived: sum of 3 quarters · filed 2023-08-10 | $217.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $108.00K 10-Q · filed 2023-05-11 | $108.00K derived: sum of 2 quarters · filed 2023-05-11 | $108.00K derived: sum of 3 quarters · filed 2023-05-11 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $0.00 derived: sum of 2 quarters · filed 2023-03-06 | $0.00 10-K · filed 2023-03-06 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $0.00 10-Q · filed 2022-11-14 | ||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |